Do representatives have to report adverse events for competitor products?
- Clause 17 (15) Representatives
- Clause 17 (15) Contract Representatives
- Clause 17.3 (15.3) Hospitality and Payments for Events/Meetings
- Clause 17.3 (15.3) Items Delivered by Representatives
- Clause 17.3 (15.3) Health Professionals’ Standards of Conduct
- Clause 17.4 (15.4) Frequency and Manner of Calls on Doctors and Other Prescribers
- Clause 17.8 (15.8) Provision of the Summary of Product Characteristics
- Clause 17.9 (15.9) Briefing Material
Pharmaceutical companies must ensure that their staff are trained including on relevant pharmacovigilance requirements. If a representative is advised of an adverse event with a competitor medicine they should as a minimum advise the health professional that this should be reported via the yellow card scheme. Clause 9.2